Search alternatives:
larger decrease » marked decrease (Expand Search)
large decrease » marked decrease (Expand Search), large increases (Expand Search), large degree (Expand Search)
i large » ai large (Expand Search), _ large (Expand Search), a large (Expand Search)
Showing 21 - 40 results of 2,394 for search '(( i large decrease ) OR ( c ((large decrease) OR (larger decrease)) ))', query time: 0.66s Refine Results
  1. 21
    Image 5_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif

    Image 5_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  2. 22
    Image 4_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif

    Image 4_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  3. 23
    Image 3_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif

    Image 3_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  4. 24
    Image 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif

    Image 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  5. 25
    Image 6_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif

    Image 6_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.tif by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  6. 26
    Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive health behaviors (dark blue lines) compared to those who did not (light blue lines).

    Average self-reported physical health ratings before or during the COVID-19 pandemic among individuals who engaged during the pandemic in more than 3 (A), 4 (B), or 5 (C) positive... by Elie Mulhem (22537863)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 27
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 28
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 29
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 30
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 31
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 32
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 33
    Data Sheet 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf

    Data Sheet 2_Large scale deletion and rebalancing within the k1C kafirin family in sorghum.pdf by Tyler W. Ferris (22481194)

    Published 2025
    Save to List
    Saved in:
  14. 34
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 35
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 36
    Results of SD-TOPSIS application ‐ combinations C1-C10.

    Results of SD-TOPSIS application ‐ combinations C1-C10. by Roman Vavrek (13200141)

    Published 2024
    Save to List
    Saved in:
  17. 37
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 38
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 39
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 40
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: